Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 36th Annual Health Care Conference in New York on Monday, March 7, 2016, at 2:40 p.m. ET.
A live webcast of the presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of the presentation will be available on the company website for 30 days.
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.
Media Contact Julie Rathbun Rathbun Communications [email protected] 206-769-9219 Investor Contact Shari Annes Annes Associates [email protected] 650-888-0902
